Abstract: AbstractBackgroundThere are no disease‐modifying treatments (DMTs) for Alzheimer's disease (AD). HP‐beta‐cyclodextrin (HPβCD) was effective in AD models and, in Feb 2021, clinical results were presented at a conference: a phase 1/2 trial of IV HPβCD qow for >8 h had shown reduction of CSF tau protein after 12 wk. HPβCD is known for its risk of cholesterol‐related ototoxicity, but hearing loss was only transient (Fig. 1) and the FDA accepted INDs for overnight IV HPβCD as a drug against NPC1 (phase 3) and AD (phase 2).MethodTo tes...
(read more)
Topics: 
Pharmacology
Internal medicine
Endocrinology